Compstatin
(Synonyms: 坎普他汀) 目录号 : GC15251
A peptide inhibitor of complement activation
Cas No.:206645-99-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Animal experiment: | Compstatin-perfused circuit: pig xenografts are perfused with human blood containing Compstatin (final conc. 0.088 mg/mL). Control group: pig kidneys perfused with human blood and control agent. The total fluid volume, protein concentration and amount of blood are equal in both the Compstatin and control perfusion circuits, and the perfusion is performed in both circuits simultaneously with pooled blood from the same two donors. |
References: [1]. Soulika AM, et al. Inhibition of heparin/protamine complex-induced complement activation by Compstatin in baboons. Clin Immunol. 2000 Sep;96(3):212-21. | |
Compstatin is a 13-residue cyclic peptide and a potent inhibitor of the complement system, and has species specificity.
Compstatin binds to baboon C3 and is resistant to proteolytic cleavage in baboon blood (similar to humans); Compstatin inhibits only the activation of primates' complement system[1].
Compstatin (21 mg/kg) produces complete inhibition when given as a combination of bolus injection and infusion. Compstatin completely inhibits in vivo heparin/protamine-induced complement activation without adverse effects on heart rate or systemic arterial, central venous, and pulmonary arterial pressures[1]. Pig xenografts survival is significantlylonger in the Compstatin perfused group than in the control group. At rejection the biopsy samples obtained from kidneysperfused with Compstatin show less deposition of C3 and fibrin than do the control kidneys[2].
References:
[1]. Soulika AM, et al. Inhibition of heparin/protamine complex-induced complement activation by Compstatin in baboons. Clin Immunol. 2000 Sep;96(3):212-21.
[2]. Fiane AE, et al. Compstatin, a peptide inhibitor of C3, prolongs survival of ex vivo perfused pig xenografts. Xenotransplantation. 1999 Feb;6(1):52-65.
| Cas No. | 206645-99-0 | SDF | |
| 别名 | 坎普他汀 | ||
| 化学名 | 2-((4R,5Z,7S,8Z,10S,11Z,13S,14Z,17Z,19S,20Z,22S,23Z,25S,26Z,28S,29Z,31S,32Z,34R)-10,13-bis((1H-imidazol-5-yl)methyl)-19-((1H-indol-3-yl)methyl)-34-((Z)-((2S,3S)-2-amino-1-hydroxy-3-methylpentylidene)amino)-4-((Z)-(((2S,3R)-1,3-dihydroxy-1-iminobutan-2-yl) | ||
| Canonical SMILES | CC[C@]([C@@](N)([H])/C(O)=N/[C@@](/C(O)=N/[C@@](/C(O)=N/[C@@](/C(O)=N/[C@@](/C(O)=N/[C@@](/C(O)=N/[C@@](/C(O)=N/C/C(O)=N/[C@@](/C(O)=N/[C@@](/C(O)=N/[C@@](/C(O)=N/1)([H])CCCNC(N)=N)([H])CC2=CN=CN2)([H])CC3=CN=CN3)([H])CC4=CNC5=CC=CC=C45)([H])CC(O)=O)([H]) | ||
| 分子式 | C66H99N23O17S2 | 分子量 | 1550.77 |
| 溶解度 | Soluble to 2 mg/ml in sterile water | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.6448 mL | 3.2242 mL | 6.4484 mL |
| 5 mM | 0.129 mL | 0.6448 mL | 1.2897 mL |
| 10 mM | 0.0645 mL | 0.3224 mL | 0.6448 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。